Riik: Uus-Meremaa
keel: inglise
Allikas: Medsafe (Medicines Safety Authority)
Cyclizine hydrochloride 50mg
Teva Pharma (New Zealand) Limited
Cyclizine hydrochloride 50 mg
50 mg
Tablet
Active: Cyclizine hydrochloride 50mg Excipient: Lactose monohydrate Magnesium stearate Maize starch Povidone Pregelatinised maize starch
Blister pack, PVC/PVDC/ Aluminium foil blister, 20 tablets
Restricted
Prescription
Micro Labs Ltd
Nauzene is indicated for the prevention and treatment of nausea and vomiting including motion sickness, nausea and vomiting caused by narcotic analgesics and by general anaesthetics in the post-operative period, and radiotherapy, especially for breast cancer since cyclizine does not elevate prolactin levels. Nauzene may be of value in relieving vomiting and attacks of vertigo associated with Meniere's disease and other forms of vestibular disturbance.
Package - Contents - Shelf Life: Blister pack, PVC/PVDC/ Aluminium foil blister - 20 tablets - 36 months from date of manufacture stored at or below 25°C - Bottle, Polypropylene container with polypropylene cap - 100 tablets - 36 months from date of manufacture stored at or below 25°C
2011-04-29
Version 1.0 1 NEW ZEALAND DATA SHEET 1. PRODUCT NAME (STRENGTH PHARMACEUTICAL FORM) NAUZENE (cyclizine hydrochloride tablets 50 mg) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains cyclizine hydrochloride 50 mg. Excipient with known effect: lactose monohydrate For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM White, circular, biconvex, uncoated tablet with a scoreline on one side and plain on the other. The tablet can be divided into equal doses. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS NAUZENE is indicated for the prevention and treatment of nausea and vomiting including: • motion sickness • nausea and vomiting caused by narcotic analgesics and by general anaesthetics in the post- operative period • radiotherapy, especially for breast cancer since cyclizine does not elevate prolactin levels. NAUZENE may be of value in relieving vomiting and attacks of vertigo associated with Meniere's disease and other forms of vestibular disturbance. 4.2 DOSE AND METHOD OF ADMINISTRATION Adults and children over 12 years: One tablet up to three times daily. Children 6 to 12 years: Half a tablet up to three times daily. Children under 6 years: Not recommended. _SPECIAL POPULATIONS _ Use in the Elderly: There have been no specific studies of cyclizine in the elderly. Experience has indicated that normal adult dosage is appropriate. To prevent travel sickness, NAUZENE should be taken 30 minutes before departure. 4.3 CONTRAINDICATIONS NAUZENE should not be given to individuals with known hypersensitivity to cyclizine. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE As with other anticholinergic agents, cyclizine should be used with caution and appropriate monitoring in patients with glaucoma, obstructive disease of the gastrointestinal tract and in males with possible prostatic hypertrophy. Cyclizine should be used with caution in patients with severe heart failure. In such patients, cyclizine may cause a fall in cardiac output associated with increases in heart rate, mean arteri Lugege kogu dokumenti